sat-practice-test-10-n-essay -n-answers
➤ Gửi thông báo lỗi ⚠️ Báo cáo tài liệu vi phạmNội dung chi tiết: sat-practice-test-10-n-essay -n-answers
sat-practice-test-10-n-essay -n-answers
https://khothuvien.cori!Rivaroxaban vs. Dabigatran or warfarin in ‘real-world1 studies of stroke prevention in atrial fibrillation: Systematic review sat-practice-test-10-n-essay -n-answers and meta-analysisYing Bai. PhD841. Hai Deng. PhDac. Alena Shantsila. PhDa. Gregory Y H Lip. MD. FRCPad* University of Birmingham. Institute of Cardiovascular Sciences. City Hospital. Birmingham B18 7QH, United Kingdom;b Cardiovascular Center. Beijing Tongren Hospital. Capital Medical University. Be sat-practice-test-10-n-essay -n-answersijing. China: c Guangdong Cardiovascular Institute. Guangdong General Hospital. Guangdong Academy ofMedical Science, Guangzhou, China;dAalborg Thrombosat-practice-test-10-n-essay -n-answers
sis Research Unit. Department of Clinical Medicine. Aalborg University.Aalborg, Denmark.Corresponding author:Professor GYH LipUniversity of Birminghamhttps://khothuvien.cori!Rivaroxaban vs. Dabigatran or warfarin in ‘real-world1 studies of stroke prevention in atrial fibrillation: Systematic review sat-practice-test-10-n-essay -n-answerstabham-acukNumber of tables 2. Number of figures 4.Key words atrial fibrillation: rivaroxaban; dabigatran: warfarin: real-world dataAbstractBackground and Purpose: This study was designed to evaluate the effectiveness and safety1of rivaroxaban in real-world practice compared with dabigatran or with sat-practice-test-10-n-essay -n-answerswarfarin for stroke prevention in atrial fibrillation (AF) through meta-analyzing observational studies.Methods 17 studies were included after searchisat-practice-test-10-n-essay -n-answers
ng in PubMed for studies reporting the comparative effectiveness and safety of rivaroxaban vs. dabigatran(n=3). rivaroxaban vs. warfarin(n-ll) or bothhttps://khothuvien.cori!Rivaroxaban vs. Dabigatran or warfarin in ‘real-world1 studies of stroke prevention in atrial fibrillation: Systematic review sat-practice-test-10-n-essay -n-answersigatran [Stroke/TE:(1.02, 0.91-1.13, P“70.2%, N-5)], but were significantly reduced when compared to warfarin (0.75,0.64-0.85, p=45.1%. N=9). Major bleeding risk was significantly higher with rivaroxaban than dabigatran (1.38, 1.27-1.49, p=26.1%. N=5). but similar to warfarin (0.99. 0.91-1.07. p=o.o sat-practice-test-10-n-essay -n-answers%, N=6). Rivaroxaban was associated with increased all-cause mortality and gastrointestinal bleeding (GIB), but similar risk of acute myocardial infarsat-practice-test-10-n-essay -n-answers
ction (AMI) and intracranial hemorrhage (ICH) compared with dabigatran. When compared with warfarin, rivaroxaban was associated with similar risk of ahttps://khothuvien.cori!Rivaroxaban vs. Dabigatran or warfarin in ‘real-world1 studies of stroke prevention in atrial fibrillation: Systematic review sat-practice-test-10-n-essay -n-answersas as effective as dabigatran. but was more effective than warfarin for the prevention of Stroke/TE in AF patients. Major bleeding risk was significantly higher with rivaroxaban than dabigatran, as was all-cause mortality and GIB. Rivaroxaban was comparable to warfarin for major bleeding, with an in sat-practice-test-10-n-essay -n-answerscreased risk in GIB and decreased risk of ICH.2IntroductionThe use of oral anticoagulants (OACs) such as the vitamin K antagonists (VKA, eg. warfarin)sat-practice-test-10-n-essay -n-answers
in patients with atrial fibrillation (AF) results in a significant reduction in stroke, ischemic stroke (IS) and systematic thromboembolism (TE), as https://khothuvien.cori!Rivaroxaban vs. Dabigatran or warfarin in ‘real-world1 studies of stroke prevention in atrial fibrillation: Systematic review sat-practice-test-10-n-essay -n-answersulation monitoring, dietary and drug interactions, and the potential for serious bleeding if anticoagulation is poorly controlled, as reflected by a poor time in therapeutic range (TTR).2The availability of the non-vitamin K antagonist oral anticoagulants (NOACs) have changed the landscape for strok sat-practice-test-10-n-essay -n-answerse prevention in AF. and a meta-analysis of randomized clinical trials (RCTs) by Ruff et al 3 has shown that usual dose NOACs result in a significant rsat-practice-test-10-n-essay -n-answers
eduction in Stroke/TE and mortality with NOACs compared to warfarin, with a trend towards less major bleeding and significantly lower intracranial hemhttps://khothuvien.cori!Rivaroxaban vs. Dabigatran or warfarin in ‘real-world1 studies of stroke prevention in atrial fibrillation: Systematic review sat-practice-test-10-n-essay -n-answersolled scenario, but still represent the gold standard of testing the effectiveness and safety of an intervention. Based on RCT data, indirect comparisons have been published showing how the different NOACs may perform relative to each other4 5 but only a head-to-head RCT can definitively assess the sat-practice-test-10-n-essay -n-answersrelative efficacy and safety of one NOAC against another.When a drug is licensed and used in everyday clinical practice, these drugs are then used insat-practice-test-10-n-essay -n-answers
a3broad patient population beyond the RCTs.6 Since the publication of the RCT data and regulatory approval of these drugs (rivaroxaban and dabigatran)https://khothuvien.cori!Rivaroxaban vs. Dabigatran or warfarin in ‘real-world1 studies of stroke prevention in atrial fibrillation: Systematic review sat-practice-test-10-n-essay -n-answers perform a systematic review and meta-analysis of data on the effectiveness and safety of rivaroxaban in real-world practice compared with dabigatran or with warfarin for stroke prevention in ARMethodsWe followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) and the sat-practice-test-10-n-essay -n-answers reporting Meta-analyses of Observational Studies in Epidemiology (MOOSE) when performing this meta-analysis.1314Two independent reviewers (Y. B. andsat-practice-test-10-n-essay -n-answers
H. D.) conducted a search of Medline and the Cochrane Library using the following items "atrial fibrillation”. "AF", "rivaroxaban”, “dabigatran", "warhttps://khothuvien.cori!Rivaroxaban vs. Dabigatran or warfarin in ‘real-world1 studies of stroke prevention in atrial fibrillation: Systematic review sat-practice-test-10-n-essay -n-answersviews. Disagreement was resolved by consensus.To be included in the meta-analysis, the observational studies needed to fulfill the following criteria: (i) with OACs used for stroke prevention in patients with AF: (ii) Available quantitative data on clinical events: (iii) Adjusted hazard ratios (HRs) sat-practice-test-10-n-essay -n-answers between rivaroxaban vs. dabigatran. or rivaroxaban vs. warfarin for stroke prevention in AF. The following studies4https://khothuvien.cori!were exclusat-practice-test-10-n-essay -n-answers
ded:https://khothuvien.cori!Rivaroxaban vs. Dabigatran or warfarin in ‘real-world1 studies of stroke prevention in atrial fibrillation: Systematic review https://khothuvien.cori!Rivaroxaban vs. Dabigatran or warfarin in ‘real-world1 studies of stroke prevention in atrial fibrillation: Systematic reviewGọi ngay
Chat zalo
Facebook